Literature DB >> 24605014

Pharmacotherapy of acute alcoholic hepatitis in clinical practice.

Ludovico Abenavoli1, Natasa Milic1, Samir Rouabhia1, Giovanni Addolorato1.   

Abstract

Severe alcoholic hepatitis (AH) is an acute form of alcohol induced liver disease with a poor prognosis that is seen in the patients who consume large quantities of alcohol. The diagnosis of AH is based on the appropriate alcohol intake history and is supported with clinical and histological features, and several scoring systems. Glucocorticoids are the mainstay for treating severe AH with pentoxifylline used as an alternative to steroids in addition to total alcohol abstinence. Liver transplantation is a possible therapeutic option for severe AH. Among the anti-craving medications able to improve abstinence rate, baclofen seems to be effective and safe in the alcoholic patients affected by severe liver damage.

Entities:  

Keywords:  Alcoholic liver disease; Baclofen; Glucocorticoids; Maddrey’s discriminant function; Orthotopic liver transplantation; Severe alcoholic hepatitis

Mesh:

Substances:

Year:  2014        PMID: 24605014      PMCID: PMC3942820          DOI: 10.3748/wjg.v20.i9.2159

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  76 in total

1.  Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence.

Authors:  G Colombo; R Agabio; M A Carai; C Lobina; M Pani; R Reali; G Addolorato; G L Gessa
Journal:  Alcohol Clin Exp Res       Date:  2000-01       Impact factor: 3.455

Review 2.  Alcoholic liver disease.

Authors:  Robert S O'Shea; Srinivasan Dasarathy; Arthur J McCullough
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

Review 3.  Alcoholic hepatitis.

Authors:  Michael R Lucey; Philippe Mathurin; Timothy R Morgan
Journal:  N Engl J Med       Date:  2009-06-25       Impact factor: 91.245

4.  Three months of abstinence from alcohol normalizes energy expenditure and substrate oxidation in alcoholics: a longitudinal study.

Authors:  G Addolorato; E Capristo; A V Greco; F Caputo; G F Stefanini; G Gasbarrini
Journal:  Am J Gastroenterol       Date:  1998-12       Impact factor: 10.864

5.  Depression, alcohol abuse and orocaecal transit time.

Authors:  G Addolorato; E Capristo; G Gasbarrini; G F Stefanini
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

6.  Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver.

Authors:  J Caballería; A Parés; C Brú; J Mercader; A García Plaza; L Caballería; G Clemente; L Rodrigo; J Rodés
Journal:  J Hepatol       Date:  1998-01       Impact factor: 25.083

7.  Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease.

Authors:  Lorenzo Leggio; George A Kenna; Anna Ferrulli; William H Zywiak; Fabio Caputo; Robert M Swift; Giovanni Addolorato
Journal:  Hum Psychopharmacol       Date:  2011-11-16       Impact factor: 1.672

Review 8.  Alcohol abuse and pulmonary disease.

Authors:  Darren M Boé; R William Vandivier; Ellen L Burnham; Marc Moss
Journal:  J Leukoc Biol       Date:  2009-07-14       Impact factor: 4.962

9.  Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis.

Authors:  R P Mookerjee; S Sen; N A Davies; S J Hodges; R Williams; R Jalan
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

10.  A new scoring system for prognostic stratification of patients with alcoholic hepatitis.

Authors:  Marlene Dominguez; Diego Rincón; Juan G Abraldes; Rosa Miquel; Jordi Colmenero; Pablo Bellot; Joan-Carles García-Pagán; Rosamelia Fernández; Montserrat Moreno; Rafael Bañares; Vicente Arroyo; Joan Caballería; Pere Ginès; Ramón Bataller
Journal:  Am J Gastroenterol       Date:  2008-08-21       Impact factor: 10.864

View more
  4 in total

1.  Six month abstinence rule for liver transplantation in severe alcoholic liver disease patients.

Authors:  Aiman Obed; Steffen Stern; Anwar Jarrad; Thomas Lorf
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

2.  Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease.

Authors:  Terence N Bukong; Arvin Iracheta-Vellve; Banishree Saha; Aditya Ambade; Abhishek Satishchandran; Benedek Gyongyosi; Patrick Lowe; Donna Catalano; Karen Kodys; Gyongyi Szabo
Journal:  Hepatology       Date:  2016-07-22       Impact factor: 17.425

Review 3.  Ethical and allocation issues in liver transplant candidates with alcohol related liver disease.

Authors:  Mai Sedki; Aijaz Ahmed; Aparna Goel
Journal:  Transl Gastroenterol Hepatol       Date:  2022-07-25

4.  Severe Alcoholic Hepatitis Effectively Treated with Vitamin E as an Add-on to Corticosteroids.

Authors:  Yuichi Miyashima; Michihiko Shibata; Yuichi Honma; Hidehiko Matsuoka; Masaaki Hiura; Shintaro Abe; Masaru Harada
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.